Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRMA NASDAQ:KZIA NASDAQ:TPST NASDAQ:XCUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRMADermata Therapeutics$1.19-0.8%$1.26$1.10▼$8.00$4.83M0.6953,535 shs41,020 shsKZIANovogen$13.77-2.2%$12.00$4.86▼$17.40$23.28M2.17194,642 shs178,860 shsTPSTTempest Therapeutics$1.25$1.73$1.23▼$12.23$18.51M-1.8597,339 shs64,666 shsXCURExicure$2.17-22.2%$3.27$1.71▼$9.50$17.78M3.5316,582 shs126,484 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRMADermata Therapeutics-0.83%-0.83%0.00%0.00%-83.00%KZIANovogen-2.20%+20.58%+4.64%+83.36%+52.15%TPSTTempest Therapeutics0.00%-1.57%-31.69%-42.13%-81.88%XCURExicure-22.22%-23.86%-23.59%-51.02%-75.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRMADermata Therapeutics$1.19-0.8%$1.26$1.10▼$8.00$4.83M0.6953,535 shs41,020 shsKZIANovogen$13.77-2.2%$12.00$4.86▼$17.40$23.28M2.17194,642 shs178,860 shsTPSTTempest Therapeutics$1.25$1.73$1.23▼$12.23$18.51M-1.8597,339 shs64,666 shsXCURExicure$2.17-22.2%$3.27$1.71▼$9.50$17.78M3.5316,582 shs126,484 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRMADermata Therapeutics-0.83%-0.83%0.00%0.00%-83.00%KZIANovogen-2.20%+20.58%+4.64%+83.36%+52.15%TPSTTempest Therapeutics0.00%-1.57%-31.69%-42.13%-81.88%XCURExicure-22.22%-23.86%-23.59%-51.02%-75.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRMADermata Therapeutics 2.00Hold$10.00740.34% UpsideKZIANovogen 2.60Moderate Buy$23.7572.48% UpsideTPSTTempest Therapeutics 1.50ReduceN/AN/AXCURExicure 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest DRMA, KZIA, TPST, and XCUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026XCURExicure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/11/2026KZIANovogen Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$32.006/4/2026DRMADermata Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/28/2026XCURExicure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/21/2026DRMADermata Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/14/2026TPSTTempest Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/4/2026DRMADermata Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/21/2026KZIANovogen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026KZIANovogen LaidlawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$25.004/2/2026TPSTTempest Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRMADermata TherapeuticsN/AN/AN/AN/A$2.19 per shareN/AKZIANovogen$30K757.35N/AN/A($5.34) per share-2.58TPSTTempest TherapeuticsN/AN/AN/AN/A$1.35 per shareN/AXCURExicure$500K27.65N/AN/A$0.62 per share3.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRMADermata Therapeutics-$7.56M-$5.31N/AN/AN/AN/A-127.91%-105.05%8/18/2026 (Estimated)KZIANovogen-$13.41MN/AN/AN/AN/AN/AN/AN/A9/4/2026 (Estimated)TPSTTempest Therapeutics-$26.26M-$6.01N/AN/AN/AN/A-355.61%-121.21%8/10/2026 (Estimated)XCURExicure-$4.95M-$1.55N/AN/AN/AN/A-179.41%-64.37%8/7/2026 (Estimated)Latest DRMA, KZIA, TPST, and XCUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2026Q1 2026XCURExicure-$18.60-$0.29+$18.31-$0.29$1.64 millionN/A5/14/2026Q1 2026TPSTTempest Therapeutics-$0.28-$2.53-$2.25-$2.53N/AN/A5/13/2026Q1 2026DRMADermata Therapeutics-$0.53-$0.48+$0.05-$0.48N/AN/A3/30/2026Q4 2025TPSTTempest Therapeutics-$0.62-$0.62N/A-$0.62N/AN/A3/26/2026Q4 2025DRMADermata Therapeutics-$1.54-$1.52+$0.02-$1.52N/AN/A3/25/2026Q4 2025XCURExicure-$18.60-$0.46+$18.14-$0.46$1.64 millionN/A3/19/2026Q2 2026KZIANovogenN/A-$1.34N/A-$1.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDRMADermata TherapeuticsN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/AN/AXCURExicureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRMADermata TherapeuticsN/A7.097.00KZIANovogenN/A2.87N/ATPSTTempest TherapeuticsN/A0.740.74XCURExicureN/A0.790.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRMADermata Therapeutics8.67%KZIANovogen30.89%TPSTTempest Therapeutics22.52%XCURExicure42.82%Insider OwnershipCompanyInsider OwnershipDRMADermata Therapeutics21.90%KZIANovogen1.00%TPSTTempest Therapeutics36.30%XCURExicure52.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRMADermata Therapeutics84.02 million3.14 millionNot OptionableKZIANovogen121.65 million1.64 millionNo DataTPSTTempest Therapeutics2014.81 million9.43 millionNo DataXCURExicure506.37 million3.01 millionNot OptionableDRMA, KZIA, TPST, and XCUR HeadlinesRecent News About These CompaniesExicure, Inc.: Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementJune 11, 2026 | finanznachrichten.deExicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementJune 10, 2026 | markets.businessinsider.comExicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementJune 10, 2026 | globenewswire.comExicure Regains Nasdaq Compliance After Late Quarterly FilingJune 1, 2026 | tipranks.comExicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-QJune 1, 2026 | globenewswire.comExicure delays quarterly filing, trims quarterly lossMay 15, 2026 | tipranks.comExicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination TherapiesApril 22, 2026 | quiverquant.comQExicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)April 22, 2026 | globenewswire.comExicure Inc.April 13, 2026 | barrons.comExicure Strengthens Leadership With New COO and DirectorApril 10, 2026 | tipranks.comSummary Notice of Pendency and Proposed Settlement of Stockholder Derivative ActionsApril 2, 2026 | globenewswire.comExicure, Inc. Reports 2025 Financial Results and Announces Need for Additional FinancingMarch 25, 2026 | quiverquant.comQExicure, Inc. Reports 2025 Financial Results and Highlights Need for Additional FinancingMarch 25, 2026 | quiverquant.comQExicure, Inc. Reports Full Year 2025 Financial ResultsMarch 25, 2026 | globenewswire.comExicure, Inc. Reports Full Year 2025 Financial ResultsMarch 25, 2026 | globenewswire.comExicure, Inc. Publishes Phase 2 Study Results for Burixafor, a Novel CXCR4 Inhibitor in Hematologic Disease TreatmentFebruary 5, 2026 | quiverquant.comQExicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing TransplantFebruary 5, 2026 | globenewswire.comExicure, Inc. to Present Phase 2 Trial Results for Burixafor at 2026 ASTCT and CIBMTR Tandem MeetingsJanuary 21, 2026 | quiverquant.comQExicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem MeetingsJanuary 21, 2026 | globenewswire.comSangsangin Investment & Securi Sells 433,332 Shares of Exicure (NASDAQ:XCUR) StockDecember 11, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDRMA, KZIA, TPST, and XCUR Company DescriptionsDermata Therapeutics NASDAQ:DRMA$1.19 -0.01 (-0.83%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$1.23 +0.04 (+3.36%) As of 04:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Novogen NASDAQ:KZIA$13.77 -0.31 (-2.20%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$13.82 +0.05 (+0.40%) As of 06/16/2026 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Tempest Therapeutics NASDAQ:TPST$1.25 0.00 (0.00%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$1.25 +0.00 (+0.40%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.Exicure NASDAQ:XCUR$2.17 -0.62 (-22.22%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$2.20 +0.03 (+1.38%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
